Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone ...
Third Quarter 2024 Net Revenues of $2.9 Million, Gross Profit of $2.2 Million and Gross Margin of 75% 2024 Net Revenue of $19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback